Research programme: obesity gene therapy - Amsterdam Molecular Therapeutics BV/University of Barcelona
Latest Information Update: 16 Jul 2012
At a glance
- Originator Amsterdam Molecular Therapeutics; University of Barcelona
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 17 Mar 2009 No development reported for Obesity in Netherlands (unspecified route)
- 19 Feb 2007 Early research in Obesity in Netherlands (unspecified route)